





Abstract

New Fluoroquinolone–Phenothiazine Hybrids and Their Antimicrobial Activity †

Marina Cassago Posso ^{*}, João Lourenço Serrano , Paulo Almeida , Fernanda Domingues, Samuel Silvestre 
and Susana Ferreira 

CICS-UBI-Health Sciences Research Centre, University of Beira Interior, 6201-506 Covilhã, Portugal; serrano.joao@hotmail.com (J.L.S.); pjsa@ubi.pt (P.A.); fcd@ubi.pt (F.D.); samuel@fcsaude.ubi.pt (S.S.); susana.ferreira@fcsaude.ubi.pt (S.F.)

* Correspondence: marina.posso@ubi.pt

† Presented at the 2nd International Electronic Conference on Antibiotics—Drugs for Superbugs: Antibiotic Discovery, Modes of Action and Mechanisms of Resistance, 15–30 June 2022; Available online: <https://eca2022.sciforum.net/>.

Keywords: hybrid; fluoroquinolones; phenothiazines; antimicrobial resistance

Antimicrobial resistance is a worldwide health problem, and with this awareness, some fluoroquinolones are classified by WHO AWaRe as “Watch”, a group with higher resistance potential. Among the known resistance mechanisms, efflux pumps have a relevant role and have been associated with multidrug resistance. Thus, the use of an efflux pump inhibitor may be an approach to restore the antibacterial activity of drugs against pathogens that cause infectious diseases. Phenothiazines have efflux-inhibiting properties and inhibit biofilm formation, which can make them a good antibacterial adjuvant. To attempt a new approach against the antimicrobial resistance of fluoroquinolones, the hybridization of ciprofloxacin and phenothiazines to afford molecules that may display antibacterial and efflux-pump-inhibitory activities were performed. The hybrid molecules were synthesized using nucleophilic substitution reactions, and the characterization of the prepared compounds was mainly performed through nuclear magnetic resonance spectroscopy. Simultaneously, to help us understand the interactions of the newly synthesized molecules and the NorA efflux pump, *in silico* studies were also carried out. The newly synthesized molecules were then evaluated regarding their potential antibacterial activity through the determination of their minimum inhibitory concentration against NorA wild-type *Staphylococcus aureus* (SA1199) and a NorA-overexpressing strain (SA1199B). The results obtained indicated that some hybrids even showed antimicrobial activity against the NorA-overexpressing strain. Future work will focus on the evaluation of the mechanisms underlying the antibacterial activity of these new molecules and the potential for restraining resistance development.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/eca2022-12722/s1>.

Author Contributions: Conceptualization, F.D., M.C.P., S.F. and S.S.; methodology, F.D., J.L.S., M.C.P., S.F. and S.S.; investigation, M.C.P.; writing—original draft preparation, M.C.P.; writing—review and editing, S.S., F.D., S.F., P.A., J.L.S. All authors have read and agreed to the published version of the manuscript.

Funding: This work was developed within the scope of the CICS-UBI projects UIDB/00709/2020 and UIDP/00709/2020, financed by national funds through the Portuguese Foundation for Science and Technology/MCTES. The NMR spectrometers are part of the Portuguese NMR Network (PTNMR) and are partially supported by the Infrastructure Project No. 022161 (co-financed by FEDER through



Citation: Posso, M.C.; Serrano, J.L.; Almeida, P.; Domingues, F.; Silvestre, S.; Ferreira, S. New Fluoroquinolone–Phenothiazine Hybrids and Their Antimicrobial Activity. *Med. Sci. Forum* **2022**, *12*, 18. <https://doi.org/10.3390/eca2022-12722>

Academic Editor: Marc Maresca

Published: 15 June 2022

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

COMPETE 2020, POCI and PORL and FCT through PIDDAC). João L. Serrano acknowledges a doctoral fellowship grant from the FCT (SFRH/BD/148028/2019).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.